Equities Analysts Set Expectations for RNTX FY2026 Earnings

Rein Therapeutics Inc. (NASDAQ:RNTX) – Research analysts at HC Wainwright boosted their FY2026 earnings estimates for Rein Therapeutics in a research note issued to investors on Tuesday, August 18th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.47) per share for the year, up from their previous forecast of ($0.53). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Rein Therapeutics’ Q4 2026 earnings at ($0.15) EPS, FY2028 earnings at ($0.67) EPS and FY2029 earnings at ($0.58) EPS.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17.

Several other analysts also recently issued reports on RNTX. Weiss Ratings raised Rein Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 3rd. Wall Street Zen raised Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Maxim Group began coverage on Rein Therapeutics in a report on Monday, July 20th. They set a “buy” rating and a $4.00 price objective for the company. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $6.00.

Rein Therapeutics Trading Up 2.8%

Shares of NASDAQ RNTX opened at $0.79 on Thursday. The firm has a market cap of $68.33 million, a PE ratio of -0.46 and a beta of 1.39. Rein Therapeutics has a 1-year low of $0.69 and a 1-year high of $2.18. The company has a fifty day moving average price of $0.88 and a 200 day moving average price of $1.12.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP acquired a new stake in Rein Therapeutics in the 3rd quarter valued at $35,000. HRT Financial LP acquired a new position in shares of Rein Therapeutics during the 4th quarter worth about $38,000. Chicago Partners Investment Group LLC grew its holdings in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after acquiring an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in shares of Rein Therapeutics in the 2nd quarter valued at about $68,000. Finally, Jane Street Group LLC acquired a new stake in shares of Rein Therapeutics in the fourth quarter valued at about $72,000. Institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.